全文获取类型
收费全文 | 49511篇 |
免费 | 3555篇 |
国内免费 | 3120篇 |
专业分类
耳鼻咽喉 | 83篇 |
儿科学 | 903篇 |
妇产科学 | 291篇 |
基础医学 | 3831篇 |
口腔科学 | 142篇 |
临床医学 | 5375篇 |
内科学 | 12301篇 |
皮肤病学 | 319篇 |
神经病学 | 1217篇 |
特种医学 | 3302篇 |
外国民族医学 | 1篇 |
外科学 | 8717篇 |
综合类 | 6403篇 |
现状与发展 | 1篇 |
预防医学 | 2971篇 |
眼科学 | 305篇 |
药学 | 4875篇 |
21篇 | |
中国医学 | 1886篇 |
肿瘤学 | 3242篇 |
出版年
2024年 | 89篇 |
2023年 | 647篇 |
2022年 | 1460篇 |
2021年 | 1890篇 |
2020年 | 1553篇 |
2019年 | 1309篇 |
2018年 | 1368篇 |
2017年 | 1318篇 |
2016年 | 1654篇 |
2015年 | 1823篇 |
2014年 | 3313篇 |
2013年 | 3326篇 |
2012年 | 3098篇 |
2011年 | 3290篇 |
2010年 | 2959篇 |
2009年 | 2894篇 |
2008年 | 2978篇 |
2007年 | 2879篇 |
2006年 | 2782篇 |
2005年 | 2308篇 |
2004年 | 1726篇 |
2003年 | 1522篇 |
2002年 | 1306篇 |
2001年 | 1174篇 |
2000年 | 985篇 |
1999年 | 774篇 |
1998年 | 685篇 |
1997年 | 632篇 |
1996年 | 546篇 |
1995年 | 489篇 |
1994年 | 487篇 |
1993年 | 357篇 |
1992年 | 344篇 |
1991年 | 265篇 |
1990年 | 222篇 |
1989年 | 219篇 |
1988年 | 206篇 |
1987年 | 146篇 |
1986年 | 128篇 |
1985年 | 147篇 |
1984年 | 118篇 |
1983年 | 90篇 |
1982年 | 95篇 |
1981年 | 103篇 |
1980年 | 79篇 |
1979年 | 72篇 |
1978年 | 69篇 |
1977年 | 51篇 |
1976年 | 47篇 |
1974年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Astrid Ruiz-Marg in Berenice M Rom n-Calleja Paulina Moreno-Guill n Jos A Gonz lez-Regueiro Deyanira K sulas-Delint Alejandro Campos-Murgu a Nayelli C Flores-Garc a Ricardo Ulises Mac as-Rodr guez 《World journal of gastrointestinal oncology》2021,13(10):1440-1452
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and presents together with cirrhosis in most cases. In addition to commonly recognized risk factors for HCC development, such as hepatitis B virus/hepatitis C virus infection, age and alcohol/tobacco consumption, there are nutritional risk factors also related to HCC development including high intake of saturated fats derived from red meat, type of cooking (generation of heterocyclic amines) and contamination of foods with aflatoxins. On the contrary, protective nutritional factors include diets rich in fiber, fruits and vegetables, n-3 polyunsaturated fatty acids and coffee. While the patient is being evaluated for staging and treatment of HCC, special attention should be paid to nutritional support, including proper nutritional assessment and therapy by a multidisciplinary team. It must be considered that these patients usually develop HCC on top of long-lasting cirrhosis, and therefore they could present with severe malnutrition. Cirrhosis-related complications should be properly addressed and considered for nutritional care. In addition to traditional methods, functional testing, phase angle and computed tomography scan derived skeletal muscle index-L3 are among the most useful tools for nutritional assessment. Nutritional therapy should be centered on providing enough energy and protein to manage the increased requirements of both cirrhosis and cancer. Supplementation with branched-chain amino acids is also recommended as it improves response to treatment, nutritional status and survival, and finally physical exercise must be encouraged and adapted to individual needs. 相似文献
22.
23.
《中国现代医生》2020,58(34):112-115
目的 探讨地佐辛术后镇痛对高龄患者围术期肝功能的影响。方法 选择2018 年1 月~2020 年6 月吉安市中心人民医院麻醉科收治的ASA 分级Ⅱ~Ⅲ级高龄患者80 例,按照随机数字表法,分为A 组、B 组、C 组、D 组,每组各20 例。分别给予0.4 mg/kg、0.5 mg/kg、0.6 mg/kg、0.7 mg/kg 地佐辛进行术后镇痛,评估术后1、2、6、12、24、48 h 患者的疼痛程度[视觉模拟评分法(VAS)]、术后镇静效果(Ramsay 评分法)及肝功能指标(ALT、AST)水平,评价不同剂量的地佐辛术后镇痛对高龄患者围术期肝功能的影响。结果 C 组术后患者不同时间段VAS 疼痛评分低于A 组、B 组、D 组,差异有统计学意义(P<0.05);四组患者术后1、2、6 h Ramsay 镇静评分比较,差异有统计学意义(P<0.05);但术后12、24、48 h Ramay 镇痛评分比较,差异无统计学意义(P>0.05)。C 组肝功能指标ALT、AST优于A 组、B 组、D 组,差异有统计学意义(P<0.05)。结论 高龄患者术后镇痛应用0.6 mg/kg地佐辛对围术期肝功能的影响最小。 相似文献
24.
《Vaccine》2020,38(33):5337-5342
Freezing of alum-based vaccines drastically alters their colloidal composition and leads to irreversible cluster formation. The loss of stability is well described, but the impact of frost damage on the functionality of the induced and secreted antibody repertoire has not been studied in detail. We therefore applied our single-cell measurement platform to extract the frequencies of Immunoglobulin G-secreting cells in combination with individual secretion rates and affinities. We showed that, frost-damaged or not, the tested vaccine was able to generate similar frequencies of total and antigen-affine IgG-secreting cells. Additionally, the frost-damaged vaccine stimulated a similar T-cell cytokine secretion pattern when compared to the regularly stored vaccine. However, frost-damaged vaccines induced no efficient affinity maturation and a complete collapse of the affinity distribution was observed. This study unveiled the impact of frost-damage to alum-based vaccines on the induced secreted antibody repertoire, and illustrated the power of functional single-antibody analysis. 相似文献
25.
26.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
27.
28.
Jennifer Wang Jonathan G. Stine Scott L. Cornella Curtis K. Argo Steven M. Cohn 《临床与转化肝病杂志(英文版)》2015,3(4):254-259
Background and Aims: Gastric antral vascular ectasia (GAVE) is commonly found in patients with cirrhosis, but it is also associated with other diseases in the absence of cirrhosis. Whether GAVE confers a different severity of gastrointestinal (GI) bleeding between patients with and without cirrhosis remains unknown. We aim to examine whether there is a difference in clinically significant GI bleeding due to GAVE in patients with or without cirrhosis. Methods: This is a retrospective case-control study of patients who were diagnosed with GAVE between January 2000 and June 2014. Patients were categorized into cirrhosis and noncirrhosis groups, and those with an additional GI bleeding source were excluded. Univariate comparisons and multivariable models were constructed using logistic regression. Results: In total, 110 patients diagnosed with GAVE on esophagogastroduodenoscopy (EGD) were included in our analysis; 84 patients had cirrhosis (76.4%) and 26 (23.6%) did not. Active GI bleeding was more prevalent in patients without cirrhosis (63.4% vs. 32.1%, p=0.003) despite similar indications for EGD, and endoscopic treatment with argon plasma coagulation (APC) was required more often in this group, approaching statistical significance (27% vs. 10.7%, p=0.056). There was no difference in bleeding severity, as evidenced by similar re-bleeding rates, surgery, or death attributed to uncontrolled bleeding. The strongest independent risk factor for GI bleeding was the absence of cirrhosis (odds ratio (OR): 5.151 (95% confidence interval (CI): 1.08-24.48, p=0.039). Conclusions: Patients with GAVE in the absence of cirrhosis are at higher risk for active GI bleeding and require more frequent endoscopic treatment than similar patients with cirrhosis. It may be worthwhile to treat GAVE in this population even in the absence of active bleeding. 相似文献
29.
Diabetes mellitus(DM) negatively affects the development and progression of chronic liver diseases(CLD) of various etiologies. Concurrent DM and CLD are also associated with worse clinical outcomes with respect to mortality, the occurrence of hepatic decompensation, and the development of hepatocellular carcinoma(HCC). Unfortunately, early diagnosis and optimal treatment of DM can be challenging, due to the lack of established clinical guidelines as well as the medical complexity of this patient population. We conducted an exploratory review of relevant literature to provide an up-to-date review for internists and hepatologists caring for this patient population. We reviewed the epidemiological and pathophysiological associations between DM and CLD, the impact of insulin resistance on the progression and manifestations of CLD, the pathogenesis of hepatogenic diabetes, as well as the practical challenges in diagnosis and monitoring of DM in this patient population. We also reviewed the latest clinical evidence on various pharmacological antihyperglycemic therapies with an emphasis on liver disease-related clinical outcomes. Finally, we proposed an algorithm for managing DM in patients with CLD and discussed the clinical and research questions that remain to be addressed. 相似文献
30.